[go: up one dir, main page]

WO2005049024A3 - Feste pharmazeutische zubereitungsform - Google Patents

Feste pharmazeutische zubereitungsform Download PDF

Info

Publication number
WO2005049024A3
WO2005049024A3 PCT/EP2004/012683 EP2004012683W WO2005049024A3 WO 2005049024 A3 WO2005049024 A3 WO 2005049024A3 EP 2004012683 W EP2004012683 W EP 2004012683W WO 2005049024 A3 WO2005049024 A3 WO 2005049024A3
Authority
WO
WIPO (PCT)
Prior art keywords
preparation form
pharmaceutical preparation
solid pharmaceutical
relates
solid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2004/012683
Other languages
English (en)
French (fr)
Other versions
WO2005049024A2 (de
Inventor
Ulrich Brauns
Thomas Friedl
Sabine Landerer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Boehringer Ingelheim Pharma GmbH and Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Original Assignee
Boehringer Ingelheim International GmbH
Boehringer Ingelheim Pharma GmbH and Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10353832A external-priority patent/DE10353832A1/de
Priority claimed from DE102004012045A external-priority patent/DE102004012045A1/de
Priority to NZ547880A priority Critical patent/NZ547880A/en
Priority to MXPA06005545A priority patent/MXPA06005545A/es
Priority to AU2004290520A priority patent/AU2004290520A1/en
Priority to CN200480034021XA priority patent/CN1882315B/zh
Priority to HK07100770.9A priority patent/HK1094676B/xx
Priority to CA2545513A priority patent/CA2545513C/en
Application filed by Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH and Co KG, Boehringer Ingelheim Pharmaceuticals Inc filed Critical Boehringer Ingelheim International GmbH
Priority to EP04818766A priority patent/EP1686965A2/de
Priority to JP2006540249A priority patent/JP2007511559A/ja
Priority to BRPI0416691-4A priority patent/BRPI0416691A/pt
Publication of WO2005049024A2 publication Critical patent/WO2005049024A2/de
Publication of WO2005049024A3 publication Critical patent/WO2005049024A3/de
Priority to IL175246A priority patent/IL175246A0/en
Anticipated expiration legal-status Critical
Priority to NO20062810A priority patent/NO20062810L/no
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Die Erfindung betrifft eine feste pharmazeutische Zubereitungsform enthaltend einen oder mehrere feste Träger- und/oder Hilfsstoffe und einen Wirkstoff aus der Gruppe der Monoamin Neurotransmitter Re-uptake Inhibitoren, welche ein 2,3-disubstituiertes Tropan Gerüst aufweisen, deren Herstellung und Verwendung zur Herstellung eines Arzneimittels zur Behandlung oder Prävention zentralnervöser Erkrankungen oder Störungen.
PCT/EP2004/012683 2003-11-18 2004-11-10 Feste pharmazeutische zubereitungsform Ceased WO2005049024A2 (de)

Priority Applications (11)

Application Number Priority Date Filing Date Title
JP2006540249A JP2007511559A (ja) 2003-11-18 2004-11-10 固形医薬製剤
BRPI0416691-4A BRPI0416691A (pt) 2003-11-18 2004-11-10 forma de preparação farmacêutica sólida
EP04818766A EP1686965A2 (de) 2003-11-18 2004-11-10 Feste pharmazeutische zubereitungsform
AU2004290520A AU2004290520A1 (en) 2003-11-18 2004-11-10 Solid pharmaceutical preparation form
CN200480034021XA CN1882315B (zh) 2003-11-18 2004-11-10 固态医药制剂形式
HK07100770.9A HK1094676B (en) 2003-11-18 2004-11-10 Solid pharmaceutical preparation form
CA2545513A CA2545513C (en) 2003-11-18 2004-11-10 Solid pharmaceutical preparation form
NZ547880A NZ547880A (en) 2003-11-18 2004-11-10 Solid pharmaceutical preparation form
MXPA06005545A MXPA06005545A (es) 2003-11-18 2004-11-10 Preparacion farmaceutica solida.
IL175246A IL175246A0 (en) 2003-11-18 2006-04-27 Solid pharmaceutical preparation form
NO20062810A NO20062810L (no) 2003-11-18 2006-06-15 Fast farmasoytisk preparatform

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE10353832.1 2003-11-18
DE10353832A DE10353832A1 (de) 2003-11-18 2003-11-18 Feste pharmazeutische Zubereitungsform
DE102004012045.5 2004-03-11
DE102004012045A DE102004012045A1 (de) 2004-03-11 2004-03-11 Feste pharmazeutische Zubereitungsform

Publications (2)

Publication Number Publication Date
WO2005049024A2 WO2005049024A2 (de) 2005-06-02
WO2005049024A3 true WO2005049024A3 (de) 2006-03-30

Family

ID=34621295

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/012683 Ceased WO2005049024A2 (de) 2003-11-18 2004-11-10 Feste pharmazeutische zubereitungsform

Country Status (17)

Country Link
US (2) US20050124651A1 (de)
EP (1) EP1686965A2 (de)
JP (2) JP2007511559A (de)
KR (1) KR20060125805A (de)
AR (1) AR046709A1 (de)
AU (1) AU2004290520A1 (de)
BR (1) BRPI0416691A (de)
CA (1) CA2545513C (de)
CO (1) CO5690555A2 (de)
IL (1) IL175246A0 (de)
MX (1) MXPA06005545A (de)
NO (1) NO20062810L (de)
NZ (1) NZ547880A (de)
PE (1) PE20050479A1 (de)
RU (1) RU2377987C2 (de)
TW (1) TW200529844A (de)
WO (1) WO2005049024A2 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1686965A2 (de) * 2003-11-18 2006-08-09 Boehringer Ingelheim International GmbH Feste pharmazeutische zubereitungsform
WO2007028769A1 (en) * 2005-09-05 2007-03-15 Neurosearch A/S Monoamine neurotransmitter re-uptake inhibitor for neuroprotection

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987004077A1 (en) * 1986-01-03 1987-07-16 The University Of Melbourne Gastro-oesophageal reflux composition
WO1997030997A1 (en) * 1996-02-22 1997-08-28 Neurosearch A/S Tropane-derivatives, their preparation and use
WO2005039580A1 (en) * 2003-10-16 2005-05-06 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an acetylcholinesterase inhibitor

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61227524A (ja) * 1985-03-30 1986-10-09 Tooa Eiyoo Kk プラゾシン製剤及びその製法
JPS62221626A (ja) * 1986-03-20 1987-09-29 Tokyo Tanabe Co Ltd １，４−ジヒドロピリジン化合物の製剤用組成物
DE3612212A1 (de) * 1986-04-11 1987-10-15 Basf Ag Verfahren zur herstellung von festen pharmazeutischen formen
DE3830353A1 (de) * 1988-09-07 1990-03-15 Basf Ag Verfahren zur kontinuierlichen herstellung von festen pharmazeutischen formen
GB9201180D0 (en) * 1992-01-21 1992-03-11 Glaxo Group Ltd Chemical compounds
JPH07118154A (ja) * 1993-10-22 1995-05-09 Dainippon Pharmaceut Co Ltd 固体分散体および粒状製剤
FR2762316B1 (fr) * 1997-04-18 1999-12-17 Sanofi Synthelabo Derives de 5-aryl-3-(8-azabicyclo[3.2.1] octan-3-yl)-1,3,4- oxadiazol-2(3h)-one, leur preparation et leur application en therapeutique
TW580397B (en) * 1997-05-27 2004-03-21 Takeda Chemical Industries Ltd Solid preparation
DE60025750T2 (de) * 1999-11-11 2006-10-19 Kyorin Pharmaceutical Co., Ltd. Orale feste zusammensetzung
CA2401569C (en) * 2000-02-29 2009-08-18 Bristol-Myers Squibb Company Low dose entecavir formulation and use
KR100381834B1 (ko) * 2000-05-20 2003-04-26 이상득 용출성이 개선된 프란루카스트 고체분산체 조성물 및 그제조 방법
US20040106643A1 (en) * 2001-05-23 2004-06-03 Gouliaev Alex Haarh Tropane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
JP2005511639A (ja) * 2001-11-30 2005-04-28 ニューロサーチ、アクティーゼルスカブ 虚血性疾患の治療用ドパミン再取り込み阻害活性を有するトロパン誘導体
ATE536874T1 (de) * 2002-05-30 2011-12-15 Neurosearch As Dreifache monoamin-wiederaufnahmehemmer zur behandlung von chronischen schmerzen
EP1686965A2 (de) * 2003-11-18 2006-08-09 Boehringer Ingelheim International GmbH Feste pharmazeutische zubereitungsform
CA2554617A1 (en) * 2004-01-22 2005-08-04 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an n-methyl-d-aspartate (nmda) receptors antagonist

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987004077A1 (en) * 1986-01-03 1987-07-16 The University Of Melbourne Gastro-oesophageal reflux composition
WO1997030997A1 (en) * 1996-02-22 1997-08-28 Neurosearch A/S Tropane-derivatives, their preparation and use
WO2005039580A1 (en) * 2003-10-16 2005-05-06 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an acetylcholinesterase inhibitor

Also Published As

Publication number Publication date
AR046709A1 (es) 2005-12-21
IL175246A0 (en) 2006-10-31
KR20060125805A (ko) 2006-12-06
US20050124651A1 (en) 2005-06-09
RU2006121446A (ru) 2008-01-10
JP2007511559A (ja) 2007-05-10
PE20050479A1 (es) 2005-10-06
WO2005049024A2 (de) 2005-06-02
JP2011068690A (ja) 2011-04-07
NO20062810L (no) 2006-08-10
NZ547880A (en) 2010-02-26
CO5690555A2 (es) 2006-10-31
HK1094676A1 (zh) 2007-04-04
BRPI0416691A (pt) 2007-01-30
MXPA06005545A (es) 2006-08-17
CA2545513A1 (en) 2005-06-02
US20100178342A1 (en) 2010-07-15
EP1686965A2 (de) 2006-08-09
RU2377987C2 (ru) 2010-01-10
CA2545513C (en) 2013-01-08
TW200529844A (en) 2005-09-16
AU2004290520A1 (en) 2005-06-02

Similar Documents

Publication Publication Date Title
HUP0302131A2 (hu) Gyógyászati tramadolsók, ezeket tartalmazó gyógyszerkészítmények
WO2003092580A3 (en) Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor
TW200510375A (en) New compounds
TNSN07161A1 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
TW200505505A (en) Process for modifying drug crystal formation
UA102517C2 (ru) Замещенные производные морфолина и тиоморфолина, фармацевтическая композиция на их основе и их применение для производства лекарственного средства для лечения расстройства или заболевания центральной нервной системы
MXPA05003253A (es) Nuevos derivados de pirimidinamida y el uso de los mismos.
SI1506185T1 (sl) Spojine in njihova uporaba kot inhibitorji 5-HT
WO2005037798A3 (en) Amide or thiomide derivatives and their use in the treatment of pain
TW200738228A (en) Neramexane modified release matrix tablet
MEP55308A (en) New pharmaceutical compositions containing flibanserin polymorph a
WO2002030405A3 (en) Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance
WO2004087880A3 (en) Compounds and their use to treat diabetes and related disorders
GB2446341A (en) Method and system for transdermal drug delivery
BG108452A (en) Tablet comprising cetirizine and pseudoephedrine
MXPA03000439A (es) Nueva forma de (r)-n-(5-metil -8-(4-metilpiperazin -1-il) -1,2,3,4-tetrahidro-2-naftil) -4-morfolinobenzamida.
PL1853232T3 (pl) Trwałe postaci krystaliczne mesylanu bifeprunoksu, postaci dawkowania oraz sposoby ich stosowania
EA201001108A1 (ru) Диспергируемые во рту таблетки, содержащие основание эсциталопрама, и способ их получения
WO2005049024A3 (de) Feste pharmazeutische zubereitungsform
UA88284C2 (ru) Твердая лекарственная форма, которая содержит действующее вещество из группы ингибиторов обратного захвата моноаминовых нейротрансмиттеров с 2,3-двухзамещенным тропановым скелетом, способ ее получения и применения
HRP20030885A2 (en) USE OF 2-THIA-DIBENZO[e,h]AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYYTEM DISEASES AND DISORDERS
MY142361A (en) Sustained-release pharmaceutical composition for pulmonary administration
AU2001274138A1 (en) Propanolaminotetralines, preparation thereof and compositions containing same
IL160486A0 (en) Citalopram for the treatment of elevated blood pressure
HRP20030957A2 (en) USE OF 1-THIA-3-AZA-DIBENZO[e,h]AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480034021.X

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004818766

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006/02999

Country of ref document: ZA

Ref document number: 200602999

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 175246

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2545513

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/005545

Country of ref document: MX

Ref document number: 06046683

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 12006500975

Country of ref document: PH

Ref document number: 2006540249

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 2004290520

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 547880

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1020067011982

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2006121446

Country of ref document: RU

ENP Entry into the national phase

Ref document number: 2004290520

Country of ref document: AU

Date of ref document: 20041110

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004290520

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2004818766

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020067011982

Country of ref document: KR

ENP Entry into the national phase

Ref document number: PI0416691

Country of ref document: BR